India, Oct. 2 -- Century Therapeutics, Inc. (IPSC), a biotechnology company, presented new nonclinical data for CNTY-813, its investigational iPSC-derived islet replacement therapy for type 1 diabetes. The data were presented in an oral presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy.
Type 1 diabetes (T1D) is a chronic autoimmune disease in which the immune system destroys insulin-producing beta cells, resulting in impaired blood glucose regulation and a need for insulin replacement.
CNTY-813 is an investigational iPSC-derived islet therapy engineered with Allo-Evasion 5.0 technology, which is designed to enable immune evasion and support an off-the-shelf cell therapy ap...